Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
The primary objectives are a) to establish the maximum tolerated dose of gemtuzumab ozogamicin in combination with cytarabine and b) to assess the safety of gemtuzumab ozogamicin when given concurrently with cytarabine.
Acute Myeloid Leukemia
Drug: Gemtuzumab Ozogamicin
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Dose Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) Given in Combination With Cytarabine in Relapsed or Refractory Patients and Alder De Novo Patients With Acute Myeloid Leukemia.|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00037596
|Study Director:||Medical Monitor, MD||Wyeth is now a wholly owned subsidiary of Pfizer|